UCB extends its BIMZELX® "Get Yourself Back" direct-to-consumer campaign for the hidradenitis suppurativa community

• Inspired by feedback from the hidradenitis suppurativa (HS) community, the campaign aims to raise awareness of BIMZELX and features a broad range of educational materials encouraging patients to discuss treatment options with their healthcare providers

ATLANTA, July 8, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the expansion of its "Get Yourself Back" direct-to-consumer (DTC) advertising campaign for BIMZELX^® (bimekizumab-bkzx). This campaign aims to raise awareness of BIMZELX and offers educational resources about both BIMZELX and hidradenitis suppurativa (HS), encouraging people living with the disease to talk with their healthcare provider about whether BIMZELX is right for them. BIMZELX is the first and only approved treatment for adults with moderate-to-severe HS specifically designed to target interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines that drive the inflammatory process.^1-2 "Get Yourself Back" aims to raise awareness of the challenges faced by those living with HS, featuring the stories of real people impacted by the condition.

HS is a chronic, painful, and potentially debilitating inflammatory skin disease that is associated with systemic manifestations.^3-4 Common symptoms include inflamed nodules that look like boils and abscesses.⁵ These can occur anywhere hair follicles are found, but usually develop in areas where skin rubs together, like armpits, the groin area, and the inner thighs.^5-6 HS lesions tend to heal slowly and come back often, leading to tunnels under the skin and scarring.^5-6

"The impact of HS extends beyond physical symptoms. People living with HS experience stigma that affects all areas of life, including interpersonal relationships, education, and work – and this stigma can prevent them from seeking treatment," said Brittany Blair, U.S. Head, Patient Strategy & Solutions, Immunology, UCB. "Awareness about treatment options, like BIMZELX, is crucial for ensuring patients are well-informed, can have open discussions with their doctors, and have access to treatments that can offer relief and help them regain control of their lives."

In addition to new TV commercials spotlighting three real patients, "Get Yourself Back" includes informational videos and interactive tools and resources for those seeking management options, daily care, and information about HS.

The campaign includes:

• Stories from real people living with HS, including a patient receiving BIMZELX, that showcase their journeys, from living covered up to throwing away some of the items that once held them back, like extra bandages and additional layers of clothing
• BIMZELX TV commercials, complemented with integrated digital and social ads, and in-office promotional materials
• A robust website featuring educational content about BIMZELX and HS, including a downloadable discussion guide to empower patient conversations with healthcare professionals

BIMZELX was approved in the U.S. for the treatment of adult patients with moderate-to-severe HS in November 2024.¹ The approval was supported by data from two Phase 3 clinical studies, which demonstrated that 48% and 52% of people treated with BIMZELX experienced at least a 50% reduction in the number of inflamed nodules and abscesses, with no increase in abscesses or draining tunnels, at 16 weeks. In comparison, 29% and 32% of people taking a placebo saw similar results.²

Through BIMZELX Navigate^®, UCB offers tailored support to patients who have been prescribed BIMZELX. Upon enrollment, patients will be offered support from a dedicated Nurse Navigator. This licensed, registered nurse will be available to discuss treatment goals, provide training assistance to patients on how to administer BIMZELX, connect eligible patients to financial assistance, and keep patients up-to-date about their BIMZELX shipment and insurance coverage status. Patients who have been prescribed BIMZELX may enroll in BIMZELX Navigate at https://www.bimzelx.com/patients-support.

"At UCB, we believe in putting patients at the center of everything we do. This campaign underscores our ongoing dedication to providing meaningful support and resources to those living with HS," said Camille Lee, Head of U.S. Immunology, UCB. "We are committed to empowering patients with the tools they need to manage their condition and improve their quality of life."

Notes to editors:

About Hidradenitis Suppurativa (HS)
Hidradenitis suppurativa (HS) is a chronic, painful, and potentially debilitating inflammatory skin disease that is associated with systemic manifestations.^3-4 The main symptoms are nodules, abscesses, and pus-discharging draining tunnels (or sinus tracts leading out of the skin) that typically occur in the armpits, groin, and buttocks, but can occur anywhere on the body there are hair follicles. ^3-4 People with HS experience flare-ups of the disease as well as severe pain, which can have a major impact on quality of life.^3-4 HS develops in early adulthood and affects approximately one percent of the population in most studied countries.^3-4

About BIMZELX^® (bimekizumab-bkzx)
BIMZELX is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes.¹ IL-17A and IL-17F are key contributors of chronic inflammation and damage across multiple tissues, with IL-17F increasing over time.^1,7-9 IL-17F is over-expressed in skin and highly elevated in the serum of patients with psoriasis (PSO), psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSpA), ankylosing spondylitis (AS), and hidradenitis suppurativa (HS).^1,7-10

The approved indications for BIMZELX in the U.S. are:¹

• Plaque psoriasis: BIMZELX is approved for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
• Psoriatic arthritis: BIMZELX is indicated for the treatment of adult patients with active psoriatic arthritis 
• Non-radiographic axial spondyloarthritis: BIMZELX is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation 
• Ankylosing spondylitis: BIMZELX is indicated for the treatment of adult patients with active ankylosing spondylitis 
• Hidradenitis suppurativa: BIMZELX is indicated for the treatment of adult patients with moderate-to-severe hidradenitis suppurativa 

BIMZELX U.S. IMPORTANT SAFETY INFORMATION 

IMPORTANT SAFETY INFORMATION 

Suicidal Ideation and Behavior 
BIMZELX (bimekizumab-bkzx) may increase the risk of suicidal ideation and behavior (SI/B). A causal association between treatment with BIMZELX and increased risk of SI/B has not been definitively established. Prescribers should weigh the potential risks and benefits before using BIMZELX in patients with a history of severe depression or SI/B. Advise monitoring for the emergence or worsening of depression, suicidal ideation, or other mood changes. If such changes occur, instruct to promptly seek medical attention, refer to a mental health professional as appropriate, and re-evaluate the risks and benefits of continuing treatment.

Infections 
BIMZELX may increase the risk of infections, including serious infections. Do not initiate treatment with BIMZELX in patients with any clinically important active infection until the infection resolves or is adequately treated. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing BIMZELX. Instruct patients to seek medical advice if signs or symptoms suggestive of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, monitor the patient closely and do not administer BIMZELX until the infection resolves. 

Tuberculosis 
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with BIMZELX. Avoid the use of BIMZELX in patients with active TB infection. Initiate treatment of latent TB prior to administering BIMZELX. Consider anti-TB therapy prior to initiation of BIMZELX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Closely monitor patients for signs and symptoms of active TB during and after treatment. 

Liver Biochemical Abnormalities 
Elevated serum transaminases were reported in clinical trials with BIMZELX. Test liver enzymes, alkaline phosphatase, and bilirubin at baseline, periodically during treatment with BIMZELX, and according to routine patient management. If treatment-related increases in liver enzymes occur and drug-induced liver injury is suspected, interrupt BIMZELX until a diagnosis of liver injury is excluded. Permanently discontinue use of BIMZELX in patients with causally associated combined elevations of transaminases and bilirubin. Avoid use of BIMZELX in patients with acute liver disease or cirrhosis. 

Inflammatory Bowel Disease 
Cases of inflammatory bowel disease (IBD) have been reported in patients treated with IL-17 inhibitors, including BIMZELX. Avoid use of BIMZELX in patients with active IBD. During BIMZELX treatment, monitor patients for signs and symptoms of IBD and discontinue treatment if new onset or worsening of signs and symptoms occurs.

Immunizations 
Prior to initiating therapy with BIMZELX, complete all age-appropriate vaccinations according to current immunization guidelines. Avoid the use of live vaccines in patients treated with BIMZELX.

Most Common Adverse Reactions
Most common (≥ 1%) adverse reactions in plaque psoriasis and hidradenitis suppurativa include upper respiratory tract infections, oral candidiasis, headache, injection site reactions, tinea infections, gastroenteritis, herpes simplex infections, acne, folliculitis, other candida infections, and fatigue. 

Most common (≥ 2%) adverse reactions in psoriatic arthritis include upper respiratory tract infections, oral candidiasis, headache, diarrhea, and urinary tract infections. 

Most common (≥ 2%) adverse reactions in non-radiographic axial spondyloarthritis include upper respiratory tract infections, oral candidiasis, headache, diarrhea, cough, fatigue, musculoskeletal pain, myalgia, tonsillitis, transaminase increase, and urinary tract infections. 

Most common (≥ 2%) adverse reactions in ankylosing spondylitis include upper respiratory tract infections, oral candidiasis, headache, diarrhea, injection site pain, rash, and vulvovaginal mycotic infection. 

Please see Important Safety Information below and full U.S. Prescribing Information at www.UCB-USA.com/Innovation/Products/BIMZELX. 

For further information, contact UCB:

U.S. Communications
Nicole Herga
T +1.773.960.5349
email Nicole.Herga@ucb.com

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of € 6.1 billion in 2024. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCBUSA.

Forward looking statements
This document contains forward-looking statements, including, without limitation, statements containing the words "potential", "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document.

Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of UCB's information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in laws and/or rules pertaining to tax and duties or the administration of such laws and/or rules, and hiring, retention and compliance of employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems.

Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB.

UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations. 

References

US-BK-2500561
BIMZELX^® and BIMZELX Navigate^® are registered trademarks of the UCB
Group of Companies
©2025 UCB, Inc., Smyrna, GA 30080. All rights reserved. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/ucb-extends-its-bimzelx-get-yourself-back-direct-to-consumer-campaign-for-the-hidradenitis-suppurativa-community-302499427.html

SOURCE UCB